Ascendis Pharma's TransCon CNP Shows Sustained Growth Benefits in Older Achondroplasia Patients

Event summary

  • Ascendis Pharma reported 2-year data from the ApproaCH trial showing sustained growth improvements in children with achondroplasia aged ≥5 years treated with TransCon CNP (navepegritide).
  • Annualized growth velocity (AGV) for TransCon CNP-treated patients was 5.71 cm/year at Week 104, compared to 5.53 cm/year for placebo patients who crossed over to TransCon CNP.
  • The safety profile remained consistent with the overall population, with no symptomatic hypotension or bone age acceleration observed.
  • TransCon CNP, now marketed as YUVIWEL®, was approved by the FDA in February 2026 and awaits EMA decision in Q4 2026.

The big picture

Ascendis Pharma's latest data reinforces TransCon CNP's potential as a best-in-class therapy for achondroplasia, addressing a significant unmet need in a rare disease space. The sustained growth benefits observed in older patients could broaden the drug's appeal, while regulatory decisions in the U.S. and Europe will shape its commercial trajectory. The results also highlight the company's ability to leverage its TransCon technology platform to develop differentiated therapies.

What we're watching

Regulatory Momentum
Whether the EMA will follow the FDA's approval of YUVIWEL in the fourth quarter of 2026, expanding market access for TransCon CNP.
Long-Term Efficacy
How sustained growth improvements translate into long-term health and quality-of-life benefits for older achondroplasia patients.
Commercial Strategy
The pace at which Ascendis Pharma can scale commercial operations to meet demand for YUVIWEL in the U.S. and potentially Europe.